Jółkowska Justyna, Derwich Katarzyna, Dawidowska Małgorzata
Department of Molecular and Clinical Genetics, Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.
J Appl Genet. 2007;48(1):77-83. doi: 10.1007/BF03194661.
The appropriate management of haematological disorders must rely on a precise and long-term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data are not sufficient and that is why in the last decade it became the most important to improve the knowledge of haematological diseases on the basis of molecular techniques and molecular markers. The presence of residual malignant cells among normal cells is termed minimal residual disease (MRD). Nowadays a great progress has been made in the treatment of malignant diseases and in the development of reliable molecular techniques, which are characterised by high sensitivity (10-3- 10-6) and ability to distinguish between normal and malignant cells at diagnosis and during follow-up. Especially, MRD data based on quantitative analysis (RQ-PCR, RT-RQ-PCR) appear to be crucial for appropriate evaluation of treatment response in many haematological malignancies. Implementation of standardized approaches for MRD assessment into routine molecular diagnostics available in all oncohaematological centres should be regarded nowadays a crucial point in further MRD study development.
血液系统疾病的恰当管理必须依赖于对患者化疗和放疗反应的精确且长期监测。临床数据并不充分,这就是为什么在过去十年里,基于分子技术和分子标记来增进对血液系统疾病的了解变得最为重要。正常细胞中残留恶性细胞的存在被称为微小残留病(MRD)。如今,在恶性疾病治疗以及可靠分子技术的开发方面已取得了巨大进展,这些技术具有高灵敏度(10⁻³ - 10⁻⁶),并且能够在诊断和随访期间区分正常细胞和恶性细胞。特别是,基于定量分析(实时定量聚合酶链反应、逆转录实时定量聚合酶链反应)的MRD数据对于许多血液系统恶性肿瘤治疗反应的恰当评估似乎至关重要。如今,在所有肿瘤血液学中心将标准化的MRD评估方法应用于常规分子诊断,应被视为进一步开展MRD研究的关键要点。